MX394865B - Uso de plinabulina en combinación con inhibidores de punto de control inmunitario - Google Patents

Uso de plinabulina en combinación con inhibidores de punto de control inmunitario

Info

Publication number
MX394865B
MX394865B MX2017010338A MX2017010338A MX394865B MX 394865 B MX394865 B MX 394865B MX 2017010338 A MX2017010338 A MX 2017010338A MX 2017010338 A MX2017010338 A MX 2017010338A MX 394865 B MX394865 B MX 394865B
Authority
MX
Mexico
Prior art keywords
plinabulin
immune checkpoint
checkpoint inhibitors
combination
treating cancer
Prior art date
Application number
MX2017010338A
Other languages
English (en)
Spanish (es)
Other versions
MX2017010338A (es
Inventor
Gloria Tsi-Yie Lee
Lan Huang
Original Assignee
Beyondspring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beyondspring Pharmaceuticals Inc filed Critical Beyondspring Pharmaceuticals Inc
Publication of MX2017010338A publication Critical patent/MX2017010338A/es
Publication of MX394865B publication Critical patent/MX394865B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2017010338A 2015-02-12 2016-02-11 Uso de plinabulina en combinación con inhibidores de punto de control inmunitario MX394865B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562115468P 2015-02-12 2015-02-12
US201562255259P 2015-11-13 2015-11-13
PCT/US2016/017602 WO2016130839A1 (en) 2015-02-12 2016-02-11 Use of plinabulin in combination with immune checkpoint inhibitors

Publications (2)

Publication Number Publication Date
MX2017010338A MX2017010338A (es) 2017-12-20
MX394865B true MX394865B (es) 2025-03-24

Family

ID=56615698

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017010338A MX394865B (es) 2015-02-12 2016-02-11 Uso de plinabulina en combinación con inhibidores de punto de control inmunitario
MX2022007472A MX2022007472A (es) 2015-02-12 2017-08-10 Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022007472A MX2022007472A (es) 2015-02-12 2017-08-10 Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.

Country Status (16)

Country Link
US (1) US20180028531A1 (enExample)
EP (1) EP3256130A4 (enExample)
JP (4) JP7243021B2 (enExample)
KR (2) KR20240110996A (enExample)
CN (2) CN107427510A (enExample)
AU (3) AU2016219204B2 (enExample)
CA (1) CA2975729A1 (enExample)
CL (1) CL2017002050A1 (enExample)
HK (1) HK1247816A1 (enExample)
IL (2) IL286282B2 (enExample)
MX (2) MX394865B (enExample)
MY (1) MY193968A (enExample)
NZ (1) NZ734256A (enExample)
RU (1) RU2723021C2 (enExample)
SG (1) SG11201706281YA (enExample)
WO (1) WO2016130839A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20161157T1 (hr) 2009-03-30 2016-11-18 Eisai R&D Management Co., Ltd. Liposomski pripravak
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
AU2016229295B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
SG10202008673WA (en) 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
CN107921018A (zh) * 2015-06-11 2018-04-17 生态有限公司 药物组合及其应用
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
JP2019511565A (ja) 2016-02-08 2019-04-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド ツカレゾールまたはそのアナログを含む組成物
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
AU2017278245B2 (en) 2016-06-06 2022-09-15 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
JP7198666B2 (ja) 2016-08-26 2023-01-04 哲治 奥野 微小血管血流低減剤およびその利用
EP3525818A1 (en) * 2016-10-14 2019-08-21 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20240110997A (ko) 2017-02-01 2024-07-16 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
NZ778329A (en) * 2017-03-13 2026-03-27 Beyondspring Pharmaceuticals Inc Compositions of plinabulin and use thereof
US11045452B2 (en) 2017-07-26 2021-06-29 Chong Kun Dang Pharmaceutical Corp. Composition for preventing or treating cancer comprising a vascular disrupting agent and immune checkpoint inhibitor
CN111225670A (zh) 2017-09-08 2020-06-02 大学健康网络 抑制Polo样激酶4的组合疗法
CN109498627B (zh) * 2017-09-15 2021-06-04 深圳华大海洋科技有限公司 一种治疗肿瘤的药物组合物及其应用
EP3743074A4 (en) * 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
JP7500438B2 (ja) * 2018-06-01 2024-06-17 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Ｅｇｆｒ変異に関連する癌の治療組成物及び治療方法
CN108524442B (zh) * 2018-06-05 2022-01-28 深圳海王医药科技研究院有限公司 一种抗肿瘤药物的注射剂及其制备方法
EP3836930A4 (en) * 2018-08-16 2022-05-11 Beyondspring Pharmaceuticals Inc. Method and composition for stimulating immune response
WO2020092887A2 (en) * 2018-11-01 2020-05-07 North Carolina State University Adipocyte mediated delivery of anticancer therapeutics
CN110265095A (zh) * 2019-05-22 2019-09-20 首都医科大学附属北京佑安医院 用于hcc复发及rfs的预测模型和诺模图的构建方法及应用
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CN112778155B (zh) * 2019-11-11 2023-08-11 大连万春布林医药有限公司 妥卡雷琐衍生物及其用途
MX2022013808A (es) * 2020-05-04 2023-02-09 Beyondspring Pharmaceuticals Inc Terapia de combinacion triple para mejorar la eliminacion de celulas cancerigenas en canceres con baja inmunogenicidad.
WO2022133492A1 (en) * 2020-12-18 2022-06-23 Beyondspring Pharmaceuticals, Inc. Compositions and methods for generating anti-tumor immune response
WO2022216908A1 (en) * 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
CN121127241A (zh) * 2023-03-10 2025-12-12 万春药业公司 肿瘤联合治疗及使用方法
WO2025006507A1 (en) * 2023-06-27 2025-01-02 Beyondspring Pharmaceuticals, Inc. Oncology combination therapy and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60316688T2 (de) * 2002-08-02 2008-07-17 Nereus Pharmaceuticals, Inc., San Diego Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon
WO2005077940A1 (en) * 2004-02-04 2005-08-25 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
PL2161336T5 (pl) * 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
US8569262B2 (en) * 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
KR20100100949A (ko) * 2008-01-08 2010-09-15 브리스톨-마이어스 스큅 컴퍼니 증식성 질환의 치료를 위한 튜불린 조정제와 항-ｃｔｌａ４ 항체의 조합물
US8791102B2 (en) * 2008-10-17 2014-07-29 Exelixis, Inc. Acetanilide sphingosine-1-phosphate receptor antagonists
CA2939165A1 (en) * 2009-09-15 2011-03-24 Cerulean Pharma Inc. A cdp-camptothecin conjugate, particle or composition and uses thereof
US20130064831A1 (en) * 2010-05-17 2013-03-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
WO2012035436A1 (en) * 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
US20150004175A1 (en) * 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
FI3381942T4 (fi) * 2012-08-30 2025-12-16 Amgen Inc Menetelmä melanooman hoitamiseksi herpes simplex -virusta ja immuuniaktivaation vapauttajaa käyttäen
US10034939B2 (en) * 2012-10-26 2018-07-31 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
LT2958943T (lt) * 2013-02-20 2020-01-27 The Trustees Of The University Of Pennsylvania Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių
WO2014128245A1 (en) * 2013-02-21 2014-08-28 CORAL, Sandra Dna hypomethylating agents for cancer therapy
EP2994530A4 (en) * 2013-05-10 2016-11-16 Whitehead Biomedical Inst PROTEIN MODIFYING LIVING CELLS USING SORTASE
CN105658206A (zh) * 2013-06-03 2016-06-08 诺华股份有限公司 抗pd-l1抗体与mek抑制剂和/或braf抑制剂的组合
EP3076972B1 (en) * 2013-10-11 2021-10-06 BeyondSpring, Inc. Cancer treatment with combination of plinabulin and taxane
JP2019511565A (ja) * 2016-02-08 2019-04-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド ツカレゾールまたはそのアナログを含む組成物

Also Published As

Publication number Publication date
NZ750444A (en) 2021-03-26
AU2016219204A1 (en) 2017-08-24
NZ734256A (en) 2019-02-22
US20180028531A1 (en) 2018-02-01
RU2017127966A3 (enExample) 2019-06-20
KR20240110996A (ko) 2024-07-16
AU2021202416B2 (en) 2024-02-15
CN107427510A (zh) 2017-12-01
CN117100753A (zh) 2023-11-24
AU2024200672A1 (en) 2024-02-22
IL253784B (en) 2021-09-30
RU2723021C2 (ru) 2020-06-08
IL253784A0 (en) 2017-09-28
CL2017002050A1 (es) 2018-04-13
AU2024200672B2 (en) 2026-03-05
JP7564172B2 (ja) 2024-10-08
IL286282B1 (en) 2023-06-01
JP2024174070A (ja) 2024-12-13
IL286282B2 (en) 2023-10-01
HK1247816A1 (zh) 2018-10-05
BR112017016902A2 (pt) 2018-03-27
JP7243021B2 (ja) 2023-03-22
MX2017010338A (es) 2017-12-20
MX2022007472A (es) 2022-06-29
KR20170117113A (ko) 2017-10-20
EP3256130A4 (en) 2018-08-01
JP7157181B2 (ja) 2022-10-19
RU2017127966A (ru) 2019-03-12
SG11201706281YA (en) 2017-09-28
IL286282A (en) 2021-10-31
MY193968A (en) 2022-11-03
WO2016130839A1 (en) 2016-08-18
JP2018508572A (ja) 2018-03-29
CA2975729A1 (en) 2016-08-18
JP2022190005A (ja) 2022-12-22
AU2016219204B2 (en) 2021-01-21
AU2021202416A1 (en) 2021-05-20
EP3256130A1 (en) 2017-12-20
JP2021050247A (ja) 2021-04-01

Similar Documents

Publication Publication Date Title
MX2017010338A (es) Uso de plinabulina en combinación con inhibidores de punto de control inmunitario.
CO2018009096A2 (es) Composiciones que contienen tucaresol o sus análogos
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
MX2017005555A (es) Inhibidores del bromodominio.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
HUE053763T2 (hu) Immunellenõrzésipont-gátlók véreredetû rákok kezelésében történõ alkalmazásra
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
MX2015011466A (es) Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
MX389707B (es) Neurotoxinas quimericas.
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
UY36538A (es) Anticuerpos humanos contra la glicoproteína del virus del ébola
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2016002772A1 (es) Composiciones de insulina de rápida acción
MX2018006152A (es) Metodos para el tratamiento de cancer utilizando inhibidores b-raf e inhibidores de punto de control inmunologico.
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
UY37258A (es) AGENTES REVERSORES DE UNIÓN PARA ANTICUERPOS ANTI-FACTOR XI/XIa Y SUS USOS
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
MX2017012553A (es) Compuestos espirociclicos.
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico